Combining oxygen delivery and generation for targeted atherosclerosis therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Hypoxia is a key driver in atherosclerosis progression, posing a significant therapeutic challenge.
• Targeted oxygen delivery to atherosclerotic lesions is crucial for mitigating disease advancement.

Purpose of the Study:

• To develop and evaluate novel nanoparticles for targeted oxygen delivery to atherosclerotic plaques.
• To investigate the therapeutic potential of these nanoparticles in alleviating hypoxia and inhibiting atherosclerosis progression.

Main Methods:

• Fabrication of Lipid 5-doped, platelet membrane-encapsulated magnetic mesoporous organosilicon nanoparticles loaded with perfluoro-15-crown ether (PFCE) and iron oxide nanoparticles (IONPs), termed FMMON@PL.
• Evaluation of FMMON@PL for targeted delivery to macrophages within atherosclerotic plaques.
• Assessment of FMMON@PL's efficacy in reducing HIF-1α expression, oxidative stress, foam cell formation, and M1 macrophage polarization.

Main Results:

• FMMON@PL demonstrated specific targeting of macrophages in atherosclerotic plaques.
• Treatment with FMMON@PL significantly reduced hypoxia-inducible factor-1α (HIF-1α) expression.
• FMMON@PL ameliorated oxidative stress, inhibited foam cell formation, and decreased M1 macrophage polarization, thereby reducing plaque progression.

Conclusions:

• FMMON@PL nanoparticles successfully achieve targeted oxygen delivery within atherosclerotic plaques.
• Hypoxia alleviation using FMMON@PL demonstrates significant therapeutic potential for treating atherosclerosis.
• The study highlights the feasibility of using engineered nanoparticles for targeted hypoxia management in cardiovascular diseases.